Abstract 170P
Background
The KRAS gene plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). This study aimed to investigate the frequency of KRAS mutations in patients with PDAC.
Methods
From 2020 to 2023, we retrospectively analyzed the KRAS status in 45 patients with PDAC. The distribution of clinical stages and the frequency of other mutations such as NRAS and BRCA2 were also evaluated.
Results
Among 45 patients, 30 (66.7%) had KRAS mutations, with the most frequent being G12D (50%), followed by G12V (26.6%). Q61K, G12A, A146T, G12R, and G12C mutations were less common. One patient with G12V mutation also had a BRCA2 mutation. In the mutated KRAS (mKRAS) group, 13 patients (43.3%) had metastatic disease, 12 (40%) had localized disease, and 5 (16.6%) had locally advanced disease. In the wild-type KRAS (wtKRAS) group, which consisted of 15 patients (33.3%), 7 (46.7%) had metastatic disease, 5 (33.3%) had localized disease, and 3 (20%) had locally advanced disease. One patient with wtKRAS also had a germline BRCA2 mutation. The distribution of clinical stages did not differ significantly between mKRAS and wtKRAS groups. NRAS mutation analysis was conducted in 41 patients, and no mutations were detected.
Conclusions
Our study revealed a high frequency of wtKRAS in patients with PDAC. Further investigation is needed to expound the clinical significance of KRAS status in this patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract